Table 2.
Current Antiretrovirals of the 395 Study Participants at Index Visit
| na | |
|---|---|
| No antiretrovirals | 63 |
| Nucleoside/nucleotide reverse transcriptase inhibitor | 319 |
| Abacavir | 49 |
| Didanosine | 9 |
| Emtricitabine | 235 |
| Lamivudine | 72 |
| Stavudine | 4 |
| Tenofovir | 269 |
| Zidovudine | 41 |
| Non-nucleoside reverse transcriptase inhibitor | 136 |
| Efavirenz | 116 |
| Etravirine | 12 |
| Nevirapine | 8 |
| Protease Inhibitor | 188 |
| Ritonavirb | 181 |
| Atazanavir | 85 |
| Darunavir | 29 |
| Fosamprenavir | 17 |
| Indinavir | 2 |
| Lopinavir | 51 |
| Nelfinavir | 4 |
| Saquinavir | 2 |
| Tipranavir | 0 |
| Integrase inhibitor/raltegravir | 40 |
| Entry inhibitor | |
| Enfuvirtide | 1 |
| Maraviroc | 6 |
a
Number of participants receiving each treatment.
b
Of patients on protease inhibitors only 7 were not receiving ritonavir boosting; 4 patients taking nelfinavir, 2 taking atazanavir, and 1 taking fosamprenavir.